Clinical Trial Update: TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. [Phase 2]

View source ↗

Summary

A Phase 2 study testing tremelimumab plus durvalumab for non-operative management of MSI-high resectable gastric cancer and gastroesophageal junction cancer is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Gastric Cancer, Microsatellite Instability | Phase 2 | Status: ACTIVE_NOT_RECRUITING